A Comprehensive Clinical and Mechanistic Review
Author: John Murphy, M.D., M.P.H., D.P.H.
Affiliation: COVID-19 Long-haul Foundation
Abstract
Background: Alterations in taste perception (dysgeusia and ageusia) emerged as a hallmark symptom of SARS-CoV-2 infection early in the COVID-19 pandemic. While initially considered secondary to nasal congestion or olfactory disruption, subsequent evidence demonstrates that gustatory dysfunction reflects a complex interplay of viral neurotropism, epithelial injury, inflammatory dysregulation, and central nervous system involvement.
Objective: To synthesize current evidence regarding the etiology, physiology, pathology, clinical progression, and therapeutic strategies for COVID-19–associated taste dysfunction.
Methods: Narrative synthesis of peer-reviewed mechanistic, clinical, and epidemiologic studies examining gustatory dysfunction in COVID-19 and post-acute sequelae of SARS-CoV-2 infection (PASC).
Results: SARS-CoV-2–associated taste impairment arises from multiple convergent mechanisms including ACE2-mediated epithelial infection of taste bud support cells, inflammatory cytokine-mediated disruption of gustatory signaling, peripheral neuropathy of cranial nerves VII, IX, and X, and central gustatory pathway dysfunction involving the insular cortex. Clinical presentation ranges from transient hypogeusia during acute infection to persistent dysgeusia lasting months to years. Recovery trajectories are heterogeneous and may reflect regenerative capacity of taste bud progenitor cells and resolution of neuroinflammation.
Conclusions: COVID-19–related taste dysfunction represents a multi-system sensory disorder rather than a purely peripheral symptom. Therapeutic strategies remain limited but include olfactory/gustatory training, anti-inflammatory interventions, zinc supplementation, and emerging neuromodulatory approaches. Further randomized trials are needed to define disease-modifying therapies.
1. Introduction
Gustatory dysfunction became one of the earliest and most distinctive non-respiratory manifestations of coronavirus disease 2019 (COVID-19). Unlike traditional post-viral taste disorders, SARS-CoV-2–associated dysgeusia frequently occurs in the absence of nasal obstruction and often coexists with olfactory impairment, neurological symptoms, and systemic inflammatory findings.
Early clinical observations suggested that taste loss might be secondary to olfactory dysfunction; however, accumulating evidence indicates that SARS-CoV-2 directly affects the gustatory system through epithelial infection, neuroinflammatory cascades, and disruption of cranial nerve signaling pathways.
The clinical burden of persistent dysgeusia has become increasingly recognized within post-acute sequelae of SARS-CoV-2 infection (PASC), contributing to malnutrition, weight loss, depression, and reduced quality of life.
2. Physiology of Taste Perception
Taste perception is mediated by specialized chemoreceptive cells located within taste buds on the tongue, soft palate, epiglottis, and oropharynx. These cells transduce chemical stimuli into electrical signals transmitted via cranial nerves:
- Facial nerve (CN VII) – anterior two-thirds of tongue
- Glossopharyngeal nerve (CN IX) – posterior one-third
- Vagus nerve (CN X) – epiglottis and lower pharynx
Taste modalities include sweet, salty, bitter, sour, and umami, each mediated by distinct receptor families (T1R, T2R, ENaC channels).
Taste buds exhibit rapid cellular turnover (~10–14 days), dependent on basal epithelial stem cells and local trophic signaling pathways including Sonic hedgehog (SHH), Wnt/β-catenin, and Notch signaling.
This regenerative capacity normally confers resilience to injury; however, SARS-CoV-2 disrupts both peripheral epithelial integrity and neurochemical signaling.
3. Etiology of COVID-19–Associated Taste Dysfunction
3.1 Direct Viral Epithelial Injury
SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) and TMPRSS2 for cellular entry. ACE2 is expressed in oral mucosa, salivary glands, and taste bud support cells. Viral entry leads to:
- apoptosis of sustentacular taste cells
- disruption of ionic microenvironment
- impaired neurotransmitter release from taste receptor cells
3.2 Neuroinvasion and Cranial Neuropathy
Evidence suggests indirect or direct involvement of cranial nerves VII, IX, and X through:
- inflammatory neuritis
- microvascular ischemia
- immune-mediated demyelination
These processes result in reduced signal transmission from taste buds to brainstem nuclei.
3.3 Salivary Gland Dysfunction
Saliva is essential for tastant solubilization. SARS-CoV-2 infects salivary gland epithelium, resulting in:
- xerostomia
- altered enzymatic activity
- impaired tastant diffusion
3.4 Central Nervous System Involvement
Neuroimaging and postmortem studies suggest involvement of:
- insular cortex (primary gustatory cortex)
- thalamic relay nuclei
- orbitofrontal integration centers
This contributes to persistent dysgeusia even after peripheral recovery.
4. Pathophysiology
The pathophysiology of COVID-19–associated taste dysfunction is best understood as a multilevel sensory disruption model:
4.1 Peripheral Level
- Taste bud epithelial damage
- inflammatory cytokine infiltration (IL-6, TNF-α)
- altered epithelial regeneration kinetics
4.2 Neural Transmission Level
- cranial neuropathy
- impaired synaptic transmission in gustatory afferents
- microvascular injury to vasa nervorum
4.3 Central Integration Level
- cortical hypometabolism in gustatory regions
- neuroinflammatory glial activation
- disrupted multisensory integration (taste–smell–somatosensory fusion)
5. Clinical Manifestations and Progression
5.1 Acute Phase
- sudden hypogeusia or ageusia
- often within 1–5 days of infection
- may occur without nasal congestion
5.2 Subacute Phase
- partial recovery with distorted taste (dysgeusia)
- metallic, bitter, or rancid phantom sensations
- fluctuating perception of sweet/salty intensity
5.3 Chronic/Post-COVID Phase
- persistent dysgeusia >3 months
- food aversion and anorexia
- nutritional deficiency risk
- psychiatric comorbidity (anxiety, depression)
Long-term cohort data indicate that a subset of patients experience symptoms lasting >12–24 months, suggesting incomplete neural or epithelial recovery in some cases.
6. Therapeutic Strategies
6.1 Supportive Management
- dietary modification
- flavor enhancement strategies
- hydration optimization
6.2 Pharmacologic Approaches
Evidence remains limited, but studied interventions include:
- Zinc supplementation (modest benefit in epithelial repair pathways)
- Corticosteroids (used in selected inflammatory cases)
- Alpha-lipoic acid (neuroprotective potential)
- Vitamin A derivatives (epithelial regeneration support)
6.3 Olfactory–Gustatory Training
Repeated sensory exposure therapy may promote cortical reorganization and neuroplastic recovery.
6.4 Emerging Therapies
- intranasal insulin (neurotrophic effects)
- neuromodulation (transcranial stimulation of gustatory cortex)
- regenerative stem-cell approaches targeting taste bud epithelium
7. Prognosis
Prognosis is highly variable:
- Majority recover within weeks to months
- ~10–20% experience prolonged dysfunction
- Smaller subset develop chronic dysgeusia with incomplete recovery
Recovery correlates with:
- severity of acute infection
- inflammatory burden
- age and metabolic comorbidities (notably diabetes)
8. Conclusion
COVID-19–associated gustatory dysfunction represents a complex neuroepithelial disorder involving peripheral taste bud injury, cranial neuropathy, salivary gland dysfunction, and central sensory processing disruption. While most patients recover, persistent cases highlight the need for targeted regenerative and neuroprotective therapies. Future randomized controlled trials are essential to define disease-modifying interventions.
COVID-19–Associated Gustatory Dysfunction
Pathophysiology, Clinical Trajectory, and Therapeutic Strategies
Part II: Molecular Mechanisms, Histopathology, and Therapeutic Evidence Synthesis
9. Molecular Virology of Gustatory Epithelium Infection
9.1 ACE2/TMPRSS2 Expression in Oral Tissues
SARS-CoV-2 cellular entry is mediated by angiotensin-converting enzyme 2 (ACE2) and priming by TMPRSS2 protease. Single-cell RNA sequencing studies demonstrate that ACE2 is expressed not only in nasal epithelium but also in:
- taste bud supporting (sustentacular) cells
- basal epithelial progenitor cells
- salivary gland ductal epithelium
- oral keratinocytes
TMPRSS2 co-expression facilitates viral fusion and intracellular entry, enabling localized infection of gustatory microenvironments.
9.2 Viral Replication in Gustatory Structures
Experimental models demonstrate that SARS-CoV-2 can replicate in:
- lingual epithelium organoids
- salivary gland epithelial cultures
Replication leads to:
- mitochondrial dysfunction in taste bud support cells
- disruption of epithelial tight junctions (claudin-1, occludin downregulation)
- impaired paracrine signaling required for taste receptor turnover
These processes result in functional denervation-like sensory loss even without overt structural destruction.
10. Immunopathology and Cytokine-Mediated Injury
10.1 Innate Immune Activation
Infected oral epithelium triggers activation of:
- toll-like receptor 3 (TLR3) and TLR7 pathways
- NF-κB signaling cascade
- interferon-stimulated gene (ISG) response
This leads to a localized inflammatory milieu characterized by elevated:
- IL-6
- TNF-α
- IFN-γ
- CXCL10
10.2 Cytokine Effects on Taste Bud Function
Inflammatory cytokines directly impair gustatory signaling:
- IL-6 reduces taste receptor cell excitability
- TNF-α induces apoptosis of basal progenitor cells
- IFN-γ disrupts synaptic transmission between taste cells and afferent nerves
The net result is functional hypogeusia disproportionate to structural injury, explaining early COVID-19 sensory loss even in mild disease.
11. Neuroinvasion and Central Gustatory Dysfunction
11.1 Cranial Nerve Involvement
Evidence supports involvement of:
- Facial nerve (CN VII) via chorda tympani
- Glossopharyngeal nerve (CN IX)
- Vagus nerve (CN X)
Mechanisms include:
- perineural inflammatory spread
- microvascular ischemia of vasa nervorum
- immune-mediated demyelination
11.2 Brainstem and Cortical Pathways
Gustatory signals normally converge at:
- nucleus tractus solitarius (NTS)
- ventroposteromedial nucleus of thalamus
- insular cortex (primary gustatory cortex)
- orbitofrontal integration centers
Functional imaging studies (FDG-PET and fMRI) in post-COVID patients demonstrate:
- hypometabolism in insular cortex
- altered connectivity between limbic and gustatory networks
- reduced reward response to food stimuli
These findings correlate with persistent dysgeusia and altered hedonic taste perception.
12. Histopathology of COVID-19 Gustatory Injury
12.1 Taste Bud Structural Changes
Autopsy and biopsy studies reveal:
- reduced number of fungiform papillae taste buds
- loss of Type II and Type III taste receptor cells
- basal cell depletion
- epithelial disorganization
12.2 Inflammatory Infiltration
Histologic findings include:
- CD8+ T-cell infiltration in lingual epithelium
- macrophage accumulation in subepithelial layers
- endothelial swelling in microvasculature
12.3 Regenerative Impairment
Normally, taste buds regenerate every 10–14 days. In COVID-19:
- SHH signaling is downregulated
- Wnt/β-catenin regenerative signaling is suppressed
- Notch pathway imbalance impairs differentiation of progenitor cells
This results in delayed or incomplete gustatory recovery in chronic cases.
13. Clinical Progression and Phenotypic Classification
COVID-19 gustatory dysfunction can be classified into four phenotypes:
13.1 Type I: Acute Transient Ageusia
- onset within 72 hours of infection
- full recovery within 2–3 weeks
- minimal neurological involvement
13.2 Type II: Prolonged Hypogeusia
- partial recovery over weeks to months
- persistent reduction in taste intensity
- often associated with anosmia
13.3 Type III: Dysgeusia Syndrome
- distorted taste perception (metallic, bitter, rancid)
- intermittent phantom taste sensations
- high association with neuroinflammation
13.4 Type IV: Chronic Neurogustatory Dysfunction (PASC-related)
- symptoms >3 months
- cognitive and autonomic comorbidities
- poor response to conventional therapies
14. Therapeutic Evidence Synthesis
14.1 Zinc Supplementation
Zinc plays a role in:
- taste bud cell membrane stability
- carbonic anhydrase activity in taste transduction
Clinical data:
- mixed results in randomized trials
- modest benefit in early disease
- limited effect in chronic dysgeusia
Mechanism:
- correction of subclinical zinc deficiency
- modulation of epithelial repair pathways
14.2 Corticosteroids
Rationale:
- reduction of inflammatory cytokine burden
- suppression of immune-mediated neuritis
Evidence:
- small observational studies show benefit in selected inflammatory phenotypes
- no consistent benefit in randomized controlled trials for all patients
Limitations:
- risk of immunosuppression
- unclear benefit-risk ratio in mild cases
14.3 Alpha-Lipoic Acid
Proposed mechanisms:
- antioxidant activity
- mitochondrial protection
- neuroregenerative signaling enhancement
Clinical evidence:
- small uncontrolled studies suggest improvement in dysgeusia severity scores
- need for randomized placebo-controlled trials
14.4 Olfactory and Gustatory Training Therapy
This remains the most consistently supported non-pharmacologic intervention.
Mechanism:
- promotes neuroplasticity in olfactory-gustatory cortical networks
- enhances sensory relearning via repeated exposure
Protocol:
- repeated daily exposure to standardized taste stimuli
- long-term adherence (8–12 weeks minimum)
Outcomes:
- improved subjective taste intensity
- partial recovery in chronic cases
14.5 Neuromodulation and Experimental Therapies
Emerging approaches include:
Transcranial Magnetic Stimulation (TMS)
- targeting insular cortex
- preliminary evidence of improved sensory integration
Intranasal Insulin
- enhances olfactory-gustatory coupling
- may promote neurogenesis in sensory pathways
Stem Cell–Based Regeneration
- experimental regeneration of taste bud epithelium
- still preclinical
15. Clinical Trials Landscape
15.1 Completed Trials
| Intervention | Outcome | Evidence Level |
|---|---|---|
| Zinc | Mixed improvement | Low–moderate |
| Corticosteroids | Inconsistent benefit | Low |
| ALA | Symptom improvement in small cohorts | Low |
| Smell/taste training | Most consistent benefit | Moderate |
15.2 Ongoing Trials
Current investigational areas include:
- neuroregenerative peptides
- epithelial stem cell therapy
- anti-cytokine biologics (IL-6 blockade)
- combined sensory rehabilitation protocols
16. Integrated Pathophysiological Model
COVID-19 gustatory dysfunction can be conceptualized as a three-compartment disease model:
16.1 Peripheral Compartment
- taste bud epithelial injury
- salivary gland dysfunction
16.2 Neural Compartment
- cranial nerve inflammation
- synaptic transmission impairment
16.3 Central Compartment
- cortical hypometabolism
- altered reward processing
These compartments interact dynamically, explaining variability in symptom duration and severity.
17. Prognostic Factors
Poor recovery is associated with:
- older age
- diabetes mellitus
- severe acute infection
- high inflammatory marker burden (CRP, IL-6)
- concurrent olfactory loss
Protective factors include:
- mild disease course
- early recovery of smell
- absence of systemic inflammation
18. Conclusion (Extended)
COVID-19–associated gustatory dysfunction is a complex multisystem disorder involving epithelial, neural, and central mechanisms. Unlike traditional post-viral taste disorders, SARS-CoV-2 produces a uniquely heterogeneous phenotype characterized by prolonged dysgeusia in a subset of patients.
Therapeutic options remain limited, with olfactory–gustatory training representing the most evidence-supported intervention. However, emerging neuroregenerative and immunomodulatory strategies offer potential for disease-modifying treatment.
A unified model integrating epithelial regeneration failure, neuroinflammation, and cortical sensory reorganization best explains the clinical spectrum observed in post-COVID populations.
References
- Koping C, et al. Mechanisms of COVID-19-associated olfactory dysfunction. Neuropathol Appl Neurobiol. 2024.
- Wellford SA, Moseman EA. Olfactory immune response to SARS-CoV-2. Cell Mol Immunol. 2024.
- Bischoff S, et al. Treatment of COVID-19 associated olfactory dysfunction: systematic review. Curr Allergy Asthma Rep. 2024.
- Passos JDC, et al. Long-term loss of smell and taste in COVID-19. ABCS Health Sci. 2024.
- Kim S, et al. Long-term olfactory loss post-COVID-19. World J Otorhinolaryngol. 2024.
- Mechanisms and management of COVID-19 taste disorders. PMC.
- COVID-19-induced sButowt R, von Bartheld CS. Mechanisms of COVID-19 anosmia and ageusia. ACS Chem Neurosci. 2021.mell and taste impairments review. PMC.
- Pellegrino R, et al. COVID-19 and chemosensory dysfunction. Physiol Rev. 2023.
- Cooper KW, et al. COVID-19 and taste dysfunction mechanisms. Brain Behav Immun. 2022.
- Brann DH, et al. Non-neuronal expression of SARS-CoV-2 entry genes in olfactory system. Sci Adv. 2020.
- Yan CH, et al. COVID-19 anosmia and ageusia clinical features. Int Forum Allergy Rhinol. 2020.
- Douaud G, et al. SARS-CoV-2 and brain structure changes. Nature. 2022.
- Hopkins C, et al. Long-term olfactory and gustatory dysfunction. Rhinology. 2021.
- Hannum ME, et al. Objective sensory testing in COVID-19. Chem Senses. 2020.